Salvatore  Privitera net worth and biography

Salvatore Privitera Biography and Net Worth

Insider of AtriCure
Salvatore Privitera, J.D. has served as our Chief Technical Officer since January 2020 having previously served as our Chief Technology Officer since July 2017. Prior to joining AtriCure, Mr. Privitera served as Vice President of Research and Development at Bard Medical (“BMD”), a division of C.R. Bard, Inc., where he helped grow BMD to over $1 billion in global revenue. He was responsible for a broad range of clinical platforms including Therapeutic Hypothermia, Urologic Drainage, Endourology, Brachytherapy, and Home Care where they impacted over 150 million patients on an annual basis. Prior to his role at BMD, Mr. Privitera worked for AtriCure as the Vice President of Engineering and Product Development for nine years. During his tenure at AtriCure, the company grew from a small startup into a public company, and he led development of many platform technologies including the AtriClip product line and the PMA approved Isolator® Synergy™ Ablation System. Prior to AtriCure, Mr. Privitera worked at Ethicon Endo-Surgery, a Johnson and Johnson company, in a variety of research, development and operations roles for over twelve years. Since December 2020, Mr. Privitera has served on the Board of Directors of the Cincinnati Chapter of the American Heart Association. Mr. Privitera received his B.S. from the University of Buffalo, his M.B.A. from Xavier University and his J.D. from Northern Kentucky University.

What is Salvatore Privitera's net worth?

The estimated net worth of Salvatore Privitera is at least $2.19 million as of May 30th, 2024. Mr. Privitera owns 103,290 shares of AtriCure stock worth more than $2,189,748 as of June 19th. This net worth evaluation does not reflect any other investments that Mr. Privitera may own. Additionally, Mr. Privitera receives an annual salary of $758,800.00 as Insider at AtriCure. Learn More about Salvatore Privitera's net worth.

How old is Salvatore Privitera?

Mr. Privitera is currently 57 years old. There are 7 older executives and no younger executives at AtriCure. The oldest executive at AtriCure is Mr. Douglas J. Seith, Chief Operating Officer, who is 58 years old. Learn More on Salvatore Privitera's age.

What is Salvatore Privitera's salary?

As the Insider of AtriCure, Inc., Mr. Privitera earns $758,800.00 per year. There are 5 executives that earn more than Mr. Privitera. The highest earning executive at AtriCure is Mr. Michael H. Carrel, CEO, President & Director, who commands a salary of $2,010,000.00 per year. Learn More on Salvatore Privitera's salary.

How do I contact Salvatore Privitera?

The corporate mailing address for Mr. Privitera and other AtriCure executives is 7555 INNOVATION WAY, MASON OH, 45040. AtriCure can also be reached via phone at (513) 755-4100 and via email at [email protected]. Learn More on Salvatore Privitera's contact information.

Has Salvatore Privitera been buying or selling shares of AtriCure?

In the last ninety days, Salvatore Privitera has bought $111,250.00 in AtriCure stock. Most recently, on Thursday, May 30th, Salvatore Privitera bought 5,000 shares of AtriCure stock. The stock was acquired at an average cost of $22.25 per share, with a total value of $111,250.00. Following the completion of the transaction, the insider now directly owns 103,290 shares of the company's stock, valued at $2,298,202.50. Learn More on Salvatore Privitera's trading history.

Who are AtriCure's active insiders?

AtriCure's insider roster includes Tonya Austin (Insider), Mark Collar (Director), Vinayak Doraiswamy (Insider), Scott Drake (Director), Regina Groves (Director), David Grumhaus, Jr. (Portfolio Manager), Justin Noznesky (Insider), Salvatore Privitera (Insider), Douglas Seith (COO), Sven Wehrwein (Director), and Angela Wirick (CFO). Learn More on AtriCure's active insiders.

Are insiders buying or selling shares of AtriCure?

During the last year, AtriCure insiders bought shares 1 times. They purchased a total of 5,000 shares worth more than $111,250.00. During the last year, insiders at the medical device company sold shares 7 times. They sold a total of 19,281 shares worth more than $742,976.93. The most recent insider tranaction occured on May, 30th when insider Salvatore Privitera bought 5,000 shares worth more than $111,250.00. Insiders at AtriCure own 3.2% of the company. Learn More about insider trades at AtriCure.

Information on this page was last updated on 5/30/2024.

Salvatore Privitera Insider Trading History at AtriCure

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/30/2024Buy5,000$22.25$111,250.00103,290View SEC Filing Icon  
7/30/2021Sell8,808$85.00$748,680.00View SEC Filing Icon  
7/28/2021Sell8,000$82.50$660,000.0061,227View SEC Filing Icon  
7/20/2021Sell2,000$80.00$160,000.00View SEC Filing Icon  
12/17/2020Sell10,654$51.33$546,869.8268,262View SEC Filing Icon  
12/9/2020Sell3,846$47.50$182,685.0078,916View SEC Filing Icon  
See Full Table

Salvatore Privitera Buying and Selling Activity at AtriCure

This chart shows Salvatore Privitera's buying and selling at AtriCure by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

AtriCure Company Overview

AtriCure logo
AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
Read More

Today's Range

Now: $21.20
Low: $18.94
High: $23.26

50 Day Range

MA: $22.58
Low: $19.86
High: $25.90

2 Week Range

Now: $21.20
Low: $18.94
High: $59.61


3,497,968 shs

Average Volume

538,934 shs

Market Capitalization

$1.01 billion

P/E Ratio


Dividend Yield